Montelukast (Singulair of Merck) is the largest selling anti-asthmatic drug in the world and is a major contributor to Morepen’s API business. During the last 5 years, its revenue has grown more than 400%; expected revenue for FY2012 is Rs.100 crores against Rs.25 crores for the current fiscal.
The company is also entering the Regulated markets, post patent expiry of Montelukast and has already filed Drug Master File (DMF No.02445) with USFDA authorities. The Company is in close touch, with major players for tie-ups and long term agreements.
During the quarter ending December 2010, it has achieved a top line of around Rs.54.31 crores, with a growth of around 30% on Q-to-Q basis, and 12% on year to date basis. Major contribution of the API sales comes from anti allergy drug Loratadine. We are already a market leader with more than 95% market share in US generic market for Loratadine and now Montelukast is also gaining momentum.
We are key supplier to many large multinationals companies for basic intermediates of Large Montelukast supplier and is expecting large business in this category in coming few years. The company had been focusing on Exports business, growing by 34% whereas domestic business has grown by 25%. While sales of Gluco Monitors, Digital Thermometers and Weighting Scales have gone up over 35% in the 9 months, there is a record jump in the sales of Nebulisers, which have registered an increase of 297%.
For more details visit @ http://www.morepen.com